Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.54 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.47 |
| ▸ | VCP | P55072 | 2/20 | 0.46 |
| ▸ | DRD2 | P14416 | 2/20 | 0.45 |
| ▸ | DRD3 | P35462 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3865928 | 0.89 | GPR119 (0.57) | GPR119TGFBR1VCPDRD2DRD3 | |
| SCHEMBL3875189 | 0.88 | GPR119 (0.55) | GPR119TGFBR1VCPDRD2DRD3 | |
| SCHEMBL3853616 | 0.87 | DRD2 (0.48) | VCPDRD2DRD3 | |
| SCHEMBL4492729 | 0.86 | GPR119 (0.55) | GPR119TGFBR1VCPDRD2DRD3 | |
| SCHEMBL13629867 | 0.85 | GPR119 (0.54) | GPR119TGFBR1VCPDRD2DRD3 | |
| SCHEMBL3869228 | 0.85 | GPR119 (0.54) | GPR119TGFBR1VCPDRD2DRD3 | |
| SCHEMBL3868906 | 0.83 | GPR119 (0.57) | GPR119TGFBR1VCPDRD2DRD3 | |
| SCHEMBL3867048 | 0.83 | GPR119 (0.57) | GPR119TGFBR1VCPDRD2DRD3 | |
| SCHEMBL3849025 | 0.83 | GPR119 (0.56) | GPR119TGFBR1DRD2DRD3LMNA | |
| SCHEMBL3845038 | 0.82 | DRD2 (0.47) | VCPDRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2038268-B1 | CARBONYLATED (AZA)CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS | BIOPROJET SOC CIV (FR) | 2015-11-04 | — | — | EP | disclosed |
| US-8802678-B2 | Carbonylated (aza) cyclohexanes as dopamine D3 receptor ligands | BIOPROJET (FR) | 2014-08-12 | — | — | US | disclosed |
| US-20090286801-A1 | CARBONYLATED (AZA) CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS | BIOPROJET (FR) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286801-A1 | CARBONYLATED (AZA) CYCLOHEXANES AS DOPAMINE D3 RECEPTOR LIGANDS | DRD3, TACR2, TACR1 | GPR119 61/4885TGFBR1 2001/4885VCP 3973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.